Form 4: TransDigm CFO Sarah Wynne Granted Stock Options
Insider Transaction Report
TransDigm Group's Chief Financial Officer, Sarah Wynne, was granted 8,700 stock options with an exercise price of $1,291.97, exercisable in 2029 and 2030.
Summary
- Sarah Wynne, Chief Financial Officer of TransDigm Group INC (TDG), acquired 8,700 stock options.
- The transaction date for the option grant was November 4, 2025.
- Each stock option has an exercise price of $1,291.97.
- The options are exercisable at 50% per year in 2029 and 50% in 2030, contingent on the achievement of annual operating performance targets in each respective year.
- The options expire on November 4, 2035.
- Following this transaction, Sarah Wynne beneficially owns 8,700 derivative securities (stock options).
- A Power of Attorney, signed by Sarah Wynne on October 22, 2025, authorizes specific individuals to execute and file SEC Forms 3, 4, and 5 on her behalf.
Sentiment
Score: 6
Explanation: The grant of stock options to a key executive is generally a neutral to slightly positive event, as it aligns management incentives with shareholder interests, though it is a routine compensation disclosure.
Positives
- The grant of stock options aligns the Chief Financial Officer's financial interests with the long-term performance and shareholder value of TransDigm Group.
- Performance-based vesting conditions incentivize the achievement of annual operating targets, potentially driving company growth and profitability.
Risks
- The exercisability of the stock options is subject to the achievement of annual operating performance targets in 2029 and 2030, meaning the options may not fully vest if targets are not met.
Future Outlook
The future exercisability of the granted stock options is tied to the achievement of annual operating performance targets in 2029 and 2030, indicating a forward-looking incentive structure for the Chief Financial Officer.
Industry Context
The grant of stock options to a Chief Financial Officer is a common practice in the aerospace and defense industry, as well as broader corporate sectors, to incentivize executive performance and align management interests with long-term shareholder value. This type of compensation is a standard component of executive remuneration packages.
Comparison to Industry Standards
- Granting performance-based stock options to key executives like the CFO is a widely adopted compensation strategy across various industries, including aerospace and defense, to foster long-term commitment and performance alignment.
- The structure of vesting over multiple years (2029 and 2030) with performance conditions is consistent with best practices for executive incentive plans, aiming to retain talent and drive sustained operational excellence.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization of Agent | Sarah Wynne executed a Power of Attorney, authorizing specific individuals (Armani Vadiee, Rachel Quinlan, Lisa Tortora-French, and Adrienne McFaye) to act as her attorney-in-fact for executing and filing SEC Forms 3, 4, and 5. | 10/22/2025 | This is a standard corporate governance practice to facilitate timely and accurate SEC filings for insiders, ensuring compliance with Section 16(a) of the Securities Exchange Act of 1934. |
Related Party Transactions
- The grant of 8,700 stock options to Sarah Wynne, the Chief Financial Officer, constitutes a related party transaction as it involves compensation provided to an executive officer of the company.
Stakeholder Impact
- Shareholders: The performance-based vesting of options aims to align the CFO's incentives with shareholder value creation, potentially leading to improved company performance.
- Employees: No direct impact on general employees is indicated by this filing.
- Management: The CFO receives a significant incentive package tied to future company performance.
Next Steps
- Achievement of annual operating performance targets in 2029 for 50% vesting of options.
- Achievement of annual operating performance targets in 2030 for the remaining 50% vesting of options.
Key Dates
| Date | Description |
|---|---|
| 10/22/2025 | Date Sarah Wynne signed the Power of Attorney. |
| 11/04/2025 | Date of the stock option grant transaction. |
| 2029 | Year when 50% of the options become exercisable, subject to performance targets. |
| 2030 | Year when the remaining 50% of the options become exercisable, subject to performance targets. |
| 11/04/2035 | Expiration date of the granted stock options. |
Keywords
TransDigm Group, TDG, Stock Options, Executive Compensation, Form 4, Sarah Wynne, Insider Transaction, Derivative Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.